Skip to content
Search

Latest Stories

England's entire tour of India to be held at three venues

India and England will play four tests, five Twenty20 matches and three one-dayers in February-March in India with the high-profile series restricted to just three venues due to the COVID-19 pandemic, both cricket boards said on Thursday.

The series will kick off on February 5th with Chennai hosting the opening two tests before the sides head to the Western Indian city of Ahmedabad to play the first international match at the world's largest cricket stadium.


The Motera stadium, with a capacity of 110,000, has displaced the Melbourne Cricket Ground as the world's largest cricket stadium, and was inaugurated by U.S. President Donald Trump during his visit to India in February.

The refurbished stadium will host the final two tests with the third to be played with pink balls under lights.

Motera will also hold the five T20 internationals, which will work as warm-ups for both sides ahead of the World Twenty20 later in the year in India.

"The prospect of becoming the first international side to play at the magnificent Sardar Patel Stadium in Ahmedabad adds an extra dimension to the tour and I know will be something that is a highlight for both the players and management," said Tom Harrison, the chief executive of England's cricket board.

Pune, situated about 150 kilometres from Mumbai, will host the final leg of the series consisting of three 50-over matches.

England will arrive in Chennai directly from Colombo on Jan. 27 after playing two test matches in Sri Lanka.

The series will be India's first at home since South Africa's tour in March was called off midway through due to the pandemic.

The United Arab Emirates hosted the 2020 edition of the popular Indian Premier League due to the situation with the coronavirus in India, which has seen 9.77 million infections, the second-highest in the world after the United States, with a death toll nearing 142,000.

"The BCCI prioritises health and safety of both teams and will leave no stone unturned to make sure that the tour is held adhering to all safety protocols agreed by the BCCI and ECB medical teams," BCCI secretary Jay Shah said.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less